Enhancing Chronic Kidney Disease Diagnosis: The Role of eGFR Calculations and Confirmatory Testing

Enhancing Chronic Kidney Disease Diagnosis: The Role of eGFR Calculations and Confirmatory Testing

Chronic kidney disease (CKD) is a significant global health concern, characterized by a gradual loss of kidney function over time. Early and accurate identification of CKD is crucial for effective management and treatment. Recent advancements in the estimation of glomerular filtration rate (GFR) have led to the introduction of the race-free CKD-EPI 2021 equations, which offer a more equitable approach to assessing kidney function. This article explores the implications of these developments, particularly the role of cystatin C as a confirmatory test, and provides actionable advice for clinical laboratories and healthcare practitioners.

The introduction of the CKD-EPI 2021 race-free eGFR calculation marks a pivotal moment in the clinical landscape, as it aims to eliminate racial bias that has historically influenced kidney function assessments. Traditional methods often relied on serum creatinine levels, which can be affected by various factors, including muscle mass, diet, and hydration status. The race-free model seeks to provide a more accurate and universally applicable measure of kidney function, making it a vital tool in the early detection of CKD.

However, even with the improved accuracy of the CKD-EPI 2021 calculations, relying solely on serum creatinine may not be sufficient for certain patients. Clinical practice recommendations suggest that cystatin C should be used as a confirmatory test for individuals with an estimated GFR (eGFR) using creatinine (eGFRcr) between 45-59 mL/min/1.73m², particularly when the urine albumin-to-creatinine ratio (uACR) is less than 30 mg/g. In such cases, cystatin C can provide a more reliable estimate of GFR, especially for patients where creatinine levels may not reflect true kidney function accurately.

Cystatin C is a protein that is produced at a constant rate by all nucleated cells and is eliminated by the kidneys. Its levels in the blood are less influenced by factors such as muscle mass, making it a valuable biomarker in assessing kidney function. By incorporating cystatin C testing into routine practice, healthcare professionals can enhance the accuracy of CKD diagnosis, particularly in populations where traditional creatinine-based estimates may be misleading.

Moreover, the integration of the race-free CKD-EPI 2021 equation and cystatin C testing aligns with the ongoing efforts to improve health equity in healthcare. By ensuring that all patients, regardless of race or background, receive accurate assessments of their kidney function, we can work towards reducing disparities in CKD diagnosis and treatment.